|
Rituximab
|
RIB-Y35
|
Mouse |
Anti-Rituximab Antibodies
|
Hybridoma |
|
|
|
|
|
Cetuximab
|
CEB-Y28
|
Mouse |
Anti-Cetuximab Antibodies
|
Hybridoma |
|
|
|
|
|
Adalimumab
|
ADB-Y19
|
Mouse |
Anti-Adalimumab Antibodies
|
Hybridoma |
|
|
|
|
|
DNP
|
DNP-FM2
|
Human |
FITC-Labeled Monoclonal Anti-DNP antibody, Human IgG1 Isotype Control
|
HEK293 |
|
|
|
|
|
DNP
|
DNP-FM1
|
Mouse |
FITC-Labeled Monoclonal Anti-DNP antibody, Mouse IgG1 Isotype Control (carrier free)
|
HEK293 |
|
|
|
|
|
BCMA
|
BCA-M43
|
Mouse |
Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)
|
HEK293 |
|
|
|
|
|
Dinitrophenyl (DNP)
|
DNP-M2
|
|
Monoclonal Anti-DNP antibody, Human IgG1 Isotype Control (MALS verified)
|
HEK293 |
|
|
|
|
|
Dinitrophenyl (DNP)
|
DNP-MB273
|
|
Monoclonal Anti-DNP antibody, Human IgG1 (N297A) Isotype Control (MALS verified)
|
HEK293 |
|
|
|
|
|
Rituximab
|
RIB-FY35c
|
Mouse |
FITC-Labeled Anti-Rituximab Antibodies, Mouse IgG1
|
Hybridoma |
|
|
|
|
|
Rituximab
|
RIB-Y37
|
Mouse |
Anti-Rituximab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Rituximab
|
RIB-Y36
|
Mouse |
Anti-Rituximab Antibodies (recommended for ADA assay)
|
Hybridoma |
|
|
|
|
|
Cetuximab
|
CEB-Y27
|
Mouse |
Anti-Cetuximab Antibodies (recommended for ADA assay)
|
Hybridoma |
|
|
|
|
|
Cetuximab
|
CEB-Y31
|
Mouse |
Anti-Cetuximab Antibodies (Non-Neutralizing)
|
Hybridoma |
|
|
|
|
|
Cetuximab
|
CEB-Y29
|
Mouse |
Anti-Cetuximab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Cetuximab
|
CEB-BY31
|
Mouse |
Biotinylated Anti-Cetuximab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Adalimumab
|
ADB-Y23
|
Mouse |
Anti-Adalimumab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Adalimumab
|
ADB-BY17
|
Mouse |
Biotinylated Anti-Adalimumab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Bevacizumab
|
BEB-BY13
|
Mouse |
Biotinylated Anti-Bevacizumab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Bevacizumab
|
BEB-Y10
|
Mouse |
Anti-Bevacizumab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
Bevacizumab
|
BEB-Y12
|
Mouse |
Anti-Bevacizumab Antibodies (recommended for neutralizing assay)
|
Hybridoma |
|
|
|
|
|
Bevacizumab
|
BEB-Y9
|
Mouse |
Anti-Bevacizumab Antibodies (recommended for ADA assay)
|
Hybridoma |
|
|
|
|
|
Trastuzumab
|
TRB-Y5b
|
Mouse |
Anti-Trastuzumab Antibodies (recommended for PK/PD)
|
HEK293 |
|
|
|
|
|
Trastuzumab
|
TRB-Y1
|
Mouse |
Anti-Trastuzumab Antibodies (recommended for PK/PD)
|
Hybridoma |
|
|
|
|
|
S1 protein
|
S1N-S58
|
Mouse |
Anti-SARS-CoV-2 Spike S1 Antibody, Mouse IgG1 (AS58) (Trehalose free)
|
Hybridoma |
|
|
|
|
|
S1 protein
|
S1N-S59
|
Mouse |
Anti-SARS-CoV-2 Spike S1 Antibody, Mouse IgG1 (AS59) (Trehalose free)
|
Hybridoma |
|
|
|
|
|
S1 protein
|
S1N-S58A1
|
Mouse |
Anti-SARS-CoV-2 Spike S1 Antibody, Mouse IgG1
|
Hybridoma |
|
|
|
|
|
S1 protein
|
S1N-S59A1
|
Mouse |
Anti-SARS-CoV-2 Spike S1 Antibody, Mouse IgG1
|
Hybridoma |
|
|
|
|
|
S protein RBD
|
SPD-M180
|
Human |
Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Human IgG1 (AM180）
|
HEK293 |
|
|
|
|
|
S protein RBD
|
SAD-S35
|
Human |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35)
|
HEK293 |
|
|
|
|
|
S protein RBD
|
SPD-S68
|
Human |
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG4 (AS35)
|
HEK293 |
|
|
|
|
A-Z
